According to a recent LinkedIn post from Infinitus Systems, the company is promoting a new report titled “The state of specialty drug access 2026,” based on real‑world benefit verification data collected by its AI agents. The post highlights that, in the analyzed patient pool, 95.7% retained insurance coverage and 98.7% of needed specialty drugs remained on formulary, yet therapy abandonment persists.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that the report offers granular breakdowns by state and therapeutic area, emphasizing the use of payor “ground‑truth” responses rather than surveys or projections. For investors, this points to Infinitus Systems’ focus on data‑driven insights into specialty drug access, which could enhance the value proposition of its AI‑driven benefits verification platform and support deeper engagement with life sciences and payer clients.
If the report gains traction with manufacturers, payors, and providers, it may strengthen the company’s positioning within the healthcare technology and prior‑authorization automation segment. Persistent therapy abandonment despite strong coverage and formulary retention could also underscore ongoing workflow and patient‑access frictions, potentially expanding the addressable market for Infinitus Systems’ automation and analytics offerings.